ArticleIndian journal of surgical oncology2025
Quality of Life (QoL) Among Patients with Esophageal Cancer Using Validated European Organisation for Research and Treatment of Cancer (EORTC)-A Hospital-Based Cross-Sectional Study.
Article in Indian journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal cancer has extremely aggressive nature and poor survival rate. An important Patient-Reported Outcome (PRO) indicator for assessing various clinical care pathways is quality of life (QoL). The objective of this study is to determine QoL among patients with esophageal cancer in a public sector hospital in North-East India. This prospective, cross-sectional study consisted of patients with esophageal cancer who sought oncology services between 14th July 2022 and 14th September 2022 at a tertiary public sector hospital. Validated European Organisation for Research and Treatment of Cancer [EORTC] QLQ-C30 Version 3.0 and EORTC QLQ-OES18 questionnaires were used to measure QoL. Among 57 patients, 98.2% patients had squamous cell carcinoma (SCC) where 64.9% had advanced disease. Mean scores were lower (compared to reference value) for global health (mean, 55.0; patients with unfavourable QoL [uQoL], 43.9%), physical function (mean, 68.7; uQoL, 52.6%), and role function (mean, 47.0; uQoL, 64.9%) and much higher symptom burden (fatigue, 57.9%; pain, 59.6%) was reported among our patients. Dysphagia was the major symptomatic burden (93.0%) in our patient. Patients with advanced stage disease had poor functional scores (physical functioning: stage II, 72.6; stage IVA, 64.5) and high symptom scores compared to early-stage disease. Significant association was found in regard to higher risk of dysphagia, reflux, and pain in advanced stage patients when compared to early-stage patients. The overall QoL in patients with esophageal cancer was poor. Patients with advanced cancer stage had poor QoL compared with early-stage cancer patients. Further studies in a homogenous group will guide future treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.